UBS AM’s Avadel Pharmaceuticals AVDL Stock Holding History

UBS AM’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-855	Closed	-$18.4K	–	3812
2025 Q4	$18.4K	Buy	+855	New	+$16.6K	﹤0.01%	2749
2025 Q3	–	Sell	-77,955	Closed	-$690K	–	2304
2025 Q2	$690K	Buy	77,955 +12,222	+19%	+$107K	﹤0.01%	2453
2025 Q1	$515K	Buy	65,733 +28,836	+78%	+$241K	﹤0.01%	2498
2024 Q4	$388K	Hold	36,897	–	–	﹤0.01%	2590
2024 Q3	$484K	Buy	+36,897	New	+$562K	﹤0.01%	2652

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS AM's AVDL Position: Q1 2026 in Review

UBS AM sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 855 shares — an estimated $18.4K sold.

UBS AM first reported a position in AVDL in Q3 2024 and held it in 5 quarters. The position peaked at $690K in Q2 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

UBS AM reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
UBS AM sold 855 Avadel Pharmaceuticals shares in Q1 2026, an estimated $18.4K.
UBS AM first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 5 quarters.
UBS AM's Avadel Pharmaceuticals position peaked at $690K in Q2 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.